Dendriform pulmonary ossification and pulmonary fibrosis: can progression be slowed?
- PMID: 40537269
- DOI: 10.1136/bcr-2025-266759
Dendriform pulmonary ossification and pulmonary fibrosis: can progression be slowed?
Abstract
Diffuse pulmonary ossification is a rare yet under-reported pulmonary finding. It consists of two main types which can coexist in some patients: dendriform and nodular.We present a case report of a middle-aged male who was investigated for breathlessness and diagnosed with Dendriform Pulmonary Ossification (DPO) based on CT imaging. He had a medical history of asthma (well controlled) and symptoms suggestive of obstructive sleep apnoea (OSA). Treatment was subsequently initiated for this. Follow-up of this case revealed an initial decline in pulmonary function tests (PFTs) associated with radiological development of possible Usual Interstitial Pneumonia (UIP) pattern fibrosis with stabilisation of fibrosis and PFTs after treatment of OSA was initiated.Little is known about this rare disease, specifically details surrounding the long-term projection, disease course and outcomes. It has been described as slowly progressive; however, factors contributing to progression have not been specifically identified. There is no current treatment; however, management often focuses on control of comorbidities in patients.We demonstrate one case where it seems that the progression of fibrosis and pulmonary ossification may be potentially slowed by treating the underlying inciting factor. We welcome other cases and long-term follow-up to determine if this hypothesis holds true for the wider population with this rarity. The development of a national registry for this condition would be a useful resource for clinicians and patients alike.
Keywords: Interstitial lung disease; Lung function; Respiratory system; Sleep disorders (respiratory medicine).
© BMJ Publishing Group Limited 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2021 Jul 20;7(7):CD013196. doi: 10.1002/14651858.CD013196.pub2. Cochrane Database Syst Rev. 2021. PMID: 34693988 Free PMC article.
-
Inhaled mannitol for cystic fibrosis.Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 May 1;5:CD008649. doi: 10.1002/14651858.CD008649.pub4. PMID: 29424930 Free PMC article. Updated.
-
Drug therapy for obstructive sleep apnoea in adults.Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003002. doi: 10.1002/14651858.CD003002.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2013 May 31;(5):CD003002. doi: 10.1002/14651858.CD003002.pub3. PMID: 16625567 Updated.
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical